(MTVA) MetaVia Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MTVA) MetaVia Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This MetaVia Inc. BCG Matrix helps you understand how the company’s products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual analysis, so you can see what the report looks like before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
No true star
MetaVia Inc. is still clinical-stage as of end-2025, with no approved commercial product and no disclosed market-leading franchise, so there is no classic BCG "star" today.
The profile looks more like an early pipeline asset than a market winner, since star status needs both fast growth and real revenue traction. With no product sales, there is no 2025 or 2026 market share base to support that label.
Until MetaVia Inc. secures approval and builds meaningful revenue, its BCG position stays outside the star box.
DA-1241 Phase 2a
DA-1241 is MetaVia Inc.'s lead investigational asset and the closest program to future "Star" status in the BCG matrix. It moved from Phase 1 work in T2DM into Phase 2a for MASH, which raises its strategic value because MASH has no approved drug therapy from MetaVia yet. Its progress gives MetaVia's pipeline the clearest near-term value driver.
DA-1726 preclinical
DA-1726 is a preclinical dual GLP-1 and glucagon agonist for obesity, so it sits in MetaVia Inc.’s "Star" bucket only if it clears development risk fast. The obesity market is already massive, with GLP-1 drugs driving more than $50 billion in annual sales across the class. If DA-1726 shows strong efficacy and tolerability, it could become a major growth driver.
Cardiometabolic focus
MetaVia Inc. keeps its pipeline tight around cardiometabolic disease, a space with huge need: the IDF said 537 million adults had diabetes in 2021, and WHO said 1 billion people lived with obesity in 2022. That narrow focus can lift BCG Stars only if one or two assets can win clear clinical data and stand out in a crowded field. For a small biotech, this is a high-upside, high-risk bet on depth, not breadth.
- Large unmet need supports upside
- Few assets, high concentration risk
- Value depends on trial wins
Combination therapy
MetaVia Inc.'s DA-1241 has been positioned for both standalone and combination use, so it is not limited to one trial path. That matters in BCG terms: if combo data hold up, the asset gains wider clinical utility and more partnering options. In 2025-2026, that flexibility is the main reason this Star can keep drawing capital and attention.
- Standalone plus combo use widens reach.
- Stronger data raise future option value.
- More utility can support partnering.
MetaVia’s Closest Star: DA-1241 Leads the Pipeline
MetaVia Inc. has no true Stars yet because it had no approved product or 2025/2026 product sales. DA-1241 is the closest future Star, since it is the lead asset and is in Phase 2a for MASH. DA-1726 is a higher-risk upside option in obesity, where GLP-1 drugs already top $50 billion in annual sales. The pipeline targets huge need: 537 million adults had diabetes in 2021 and 1 billion people lived with obesity in 2022.
| Asset | Status | Star case |
|---|---|---|
| DA-1241 | Phase 2a | Closest near-term driver |
| DA-1726 | Preclinical | High-upside, high-risk |
| MetaVia Inc. | No approved product | No current Star |
What is included in the product
Detailed Word Document
MetaVia Inc. BCG Matrix maps each business unit by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
MetaVia Inc. BCG Matrix to quickly spot growth, cash, and drag.
Reference Sources
Provides a traceable source trail that strengthens credibility and helps decision-makers verify key assumptions fast.
Cash Cows
No cash cow
MetaVia Inc. had no marketed drug at the end of 2025, so it did not have a mature product with repeat sales or steady cash flow. A cash cow needs proven market demand and repeatable cash generation, which MetaVia has not yet shown. With no commercial drug, the company’s profile still fits a development-stage biotech, not a cash cow.
No approved product
MetaVia Inc. has no approved product in the provided data, so the portfolio is still pre-commercial. Without an approved asset, there is no sales base to generate classic cash cows, and no 2025 or 2026 product revenue was identified here. This makes the cash-cow bucket effectively empty until a product clears approval and starts recurring sales.
No recurring royalty
MetaVia Inc. does not show a recurring royalty stream, so this Cash Cow is not visible in the latest disclosed model. Without royalty income, there is no clear self-funding commercial engine to offset burn. That leaves R and D reliant on external capital, grants, or partner support rather than steady internal cash flow.
Gemcabene Pfizer deal
Gemcabene’s Pfizer license covers research, development, manufacturing, and commercialization, so the asset can generate milestone and royalty cash if it advances. Pfizer paid a $10 million upfront fee when the deal was signed, but MetaVia has not disclosed any ongoing cash generation from this program. For a Cash Cows view, that makes Gemcabene a potential royalty stream, not a proven cash engine.
- Pfizer deal includes royalties and milestones.
- $10 million upfront fee was disclosed.
- No cash generation was disclosed.
- Cash cow status is unproven.
External funding reliance
MetaVia Inc., as a clinical-stage biotech, usually depends on equity raises or partner funding to pay for R&D, and that is normal before any product sales start. This is not a mature cash cow: cash comes in, but not from self-sustaining operations yet. The key test is whether it can fund trials without constant dilution.
- Pre-revenue funding is sector-normal.
- Equity support is not cash-cow strength.
- Commercial sales have not started yet.
MetaVia Has No Cash Cow, Only a Small Pfizer License Bet
MetaVia Inc. had no marketed drug at end-2025, so it had no true cash cow. Its only near-cash asset was the Gemcabene Pfizer license, which included milestones and royalties, plus a $10 million upfront fee. But no ongoing royalty cash was disclosed, so the bucket stays empty.
| Item | 2025/2026 data |
|---|---|
| Marketed drug | None |
| Pfizer upfront fee | $10 million |
| Royalty cash | Not disclosed |
Preview Before You Purchase
MetaVia Inc. Reference Sources
The MetaVia Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, ready-to-use report. Once purchased, it’s available for immediate download and practical use.
Dogs
ANA001 COVID-19
ANA001, MetaVia Inc.'s oral niclosamide program for moderate COVID-19, fits a weak BCG dog profile because COVID-19 is no longer a peak-pandemic growth market. Global demand has shifted from emergency treatment to routine management, with far fewer acute surges than 2020-2022. That leaves ANA001 with limited upside unless it proves clear clinical and commercial differentiation.
NB-01 neuropathy
NB-01 is a Dogs asset in MetaVia Inc.'s BCG Matrix because it targets painful diabetic neuropathy, a large but crowded pain market that affects about 20% to 30% of people with diabetes. As an older NeuroBo program, it has not shown late-stage commercial traction, which weakens its growth case. So its market impact looks limited, with little sign of near-term value creation.
NB-02 cognition
NB-02 cognition targets cognitive impairment, but MetaVia Inc. has not disclosed an approved product or an advanced clinical milestone for this asset. That keeps it in a low-visibility BCG profile, with no revenue or late-stage data point to support scale. In BCG terms, it reads more like a question mark than a star.
Legacy NeuroBo assets
Legacy NeuroBo assets are Dogs in MetaVia Inc.’s BCG Matrix because they sit outside the main growth story after the November 2024 name change. The older pipeline moved under MetaVia’s new brand, but DA-1241 and DA-1726 now look more central to capital use and strategy. In BCG terms, these legacy programs likely have low share and weak growth.
- Older NeuroBo pipeline
- Rebranded in Nov. 2024
- Less central than DA-1241 and DA-1726
No market share
MetaVia Inc’s lower-priority assets still fit the Dogs bucket because no market share or commercial sales have been disclosed, so they are low-growth and low-share by definition. In the latest filings, they contributed 0% of product sales, while the lead cardiometabolic programs remain the real value drivers.
- No disclosed market share
- No commercial sales reported
- 0% product revenue contribution
- Dogs profile fits these assets
MetaVia’s Dog Assets: No Sales, No Momentum, No Growth
MetaVia Inc.’s Dogs are older, low-share assets with weak growth and no disclosed sales. ANA001, NB-01, and legacy NeuroBo programs sit outside the main value drivers, while recent filings show 0% product revenue from these assets. With no approved products or late-stage traction, they are capital drains, not growth engines.
| Asset | Why Dog |
|---|---|
| ANA001 | Low-growth COVID-19 niche |
| NB-01 | Crowded pain market |
| Legacy assets | No sales disclosed |
Question Marks
DA-1241 GPCR119
DA-1241 is MetaVia Inc.’s novel GPCR119 agonist, still investigational with 0 approved indications as of 2026. That means it has high upside if late-stage data are strong, but it has no current market share or product sales. In a BCG Matrix, that fits a Question Mark: high potential, low present cash contribution, and a clear need for proof of efficacy and safety.
MASH Phase 2a
DA-1241 is still a Question Mark because it is only in Phase 2a for MASH, a large market where global MASH prevalence is estimated at about 5% to 6% of adults, or roughly 300 million people, and treatment options remain limited. Positive data are needed to justify the next step. Without clear efficacy and safety wins, MetaVia Inc. may struggle to move this program beyond high-risk development status.
DA-1726 dual agonist
DA-1726 is MetaVia Inc.’s oxyntomodulin analogue with GLP-1 and glucagon agonism, aimed at obesity. It is still early and unproven, so it fits the Question Mark bucket: high growth potential, but low current certainty and no disclosed 2025/2026 revenue. Its value depends on clinical data proving weight-loss efficacy and tolerability.
Obesity preclinical
MetaVia Inc.'s obesity preclinical program, led by DA-1726, is a classic "question mark" in the BCG Matrix: it is still in preclinical development, so it has no market share and no approved sales.
That means the asset has high option value, but also high risk, because value creation depends on clinical success, safety, and future capital use. Preclinical programs do not generate product revenue, so their near-term financial impact stays limited.
- DA-1726: preclinical only
- No approved obesity sales
- No current market share
- High upside, high risk
Dong-A ST collaboration
DA-1726 fits the "Question Mark" in MetaVia Inc.'s BCG Matrix: it has upside, but it is still pre-commercial. The joint research tie-up with Dong-A ST and ImmunoForge adds technical depth and helps split development risk, but it does not yet create market share or sales.
That makes it a resource claim on cash, not a cash generator, in FY2025/FY2026 terms.
- Dong-A ST boosts R&D capacity.
- ImmunoForge adds platform support.
- No commercial share yet.
- Value depends on clinical progress.
MetaVia’s High-Risk, High-Reward Pipeline Hinges on Clinical Proof
MetaVia Inc.’s Question Marks are DA-1241 and DA-1726: both have upside, but no approved sales or market share in FY2025/FY2026. DA-1241 is in Phase 2a for MASH, a market affecting about 300 million people worldwide; DA-1726 is still preclinical for obesity. Value depends on clinical proof, safety, and funding discipline.
| Asset | Status | BCG fit |
|---|---|---|
| DA-1241 | Phase 2a, MASH | Question Mark |
| DA-1726 | Preclinical, obesity | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.